Regional citrate as first choice for CRRT, heparin when citrate is unsuitable, and options in bleeding or HIT.
At the bedside
- 1
Assess bleeding and liver function
Active bleeding, recent surgery, platelets < 50 x10^9/L, coagulopathy: avoid systemic heparin. Severe liver failure or lactate > 4 mmol/L with shock: caution with citrate (accumulation).
- 2
Citrate (first choice)
Pre-filter citrate to post-filter iCa 0.25-0.35 mmol/L; calcium infusion to systemic iCa 1.0-1.2 mmol/L. Check iCa at 1 h and 6-hourly.
- 3
Detect citrate accumulation
Total Ca/ionised Ca ratio > 2.5, rising anion gap acidosis, falling systemic iCa despite increasing Ca infusion: reduce citrate/blood flow, increase dialysate, or switch method.
- 4
Heparin (if citrate unsuitable)
UFH pre-filter 5-10 units/kg/h, aPTT target 45-60 s (or per protocol); avoid in HIT.
- 5
No anticoagulation
In high bleeding risk: pre-dilution, higher blood flow (200-250 mL/min), low FF, minimise interruptions; accept shorter filter life.
- 6
HIT
Stop all heparin; use citrate or argatroban (or no anticoagulation).
Regional anticoagulation
Trisodium citrate (regional citrate anticoagulation)
- Dose
- Titrate to post-filter iCa 0.25-0.35 mmol/L
- Target
- Systemic iCa 1.0-1.2 mmol/L; total/iCa ratio < 2.5
Systemic heparin for circuit
Unfractionated heparin (CRRT circuit)
- Dose
- 5-10 units/kg/h (typically 300-1,000 units/h)
- Preparation
- 5,000 units in 50 mL NS = 100 units/mL
- Target
- aPTT 45-60 s
- Worked example
- 70 kg at 7 units/kg/h = 490 units/h = 4.9 mL/h of 100 units/mL
Calculators for this topic
References
- 1
- 2
Choosing CRRT anticoagulation
Step 1 of ~4
Decision: High bleeding risk?
Based on Kidney Disease: Improving Global Outcomes (KDIGO) AKI Work Group; Zarbock A, Kullmar M, Kindgen-Milles D, et al. Educational use; follow local protocol.
Pathophysiology
Citrate chelates ionised calcium in the circuit, blocking the coagulation cascade only in the filter. Most citrate-calcium complexes are removed in the effluent; the remainder is metabolised (liver, muscle) to bicarbonate. Accumulation occurs when metabolism fails.
Evidence
- RICH (596 patients): citrate vs heparin - longer filter life (47 vs 26 h), fewer bleeding complications, no 90-day mortality difference; more new infections in citrate group [Zarbock 2020].
- KDIGO 2012 suggests citrate for CRRT in patients without contraindications [KDIGO 2012].
Controversies
- Citrate in liver failure: increasingly used with careful monitoring.
🇮🇳 India notes
- Citrate solutions are not available in many Indian ICUs; heparin or no-anticoagulation CRRT/SLED is common. Filter cost makes filter life an important outcome.
References
- 1
- 2
Test yourself
Module quiz · score 70% to complete the module
Educational reference for trained clinicians. Check doses against your hospital protocol and the patient in front of you.

